- Home
- SY vs AVTX Comparison
SY vs AVTX Comparison
Compare SY & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SY
- AVTX
- Stock Information
- Founded
- SY 2013
- AVTX 2011
- Country
- SY China
- AVTX United States
- Employees
- SY N/A
- AVTX N/A
- Industry
- SY EDP Services
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- SY Technology
- AVTX Health Care
- Exchange
- SY Nasdaq
- AVTX Nasdaq
- Market Cap
- SY 98.6M
- AVTX 88.4M
- IPO Year
- SY 2019
- AVTX 2015
- Fundamental
- Price
- SY $0.87
- AVTX $7.99
- Analyst Decision
- SY Hold
- AVTX Strong Buy
- Analyst Count
- SY 1
- AVTX 5
- Target Price
- SY $0.80
- AVTX $36.75
- AVG Volume (30 Days)
- SY 105.9K
- AVTX 98.4K
- Earning Date
- SY 03-20-2025
- AVTX 03-28-2025
- Dividend Yield
- SY 6.90%
- AVTX N/A
- EPS Growth
- SY 1.45
- AVTX N/A
- EPS
- SY 0.05
- AVTX N/A
- Revenue
- SY $212,139,568.00
- AVTX $820,000.00
- Revenue This Year
- SY $2.13
- AVTX N/A
- Revenue Next Year
- SY $4.64
- AVTX N/A
- P/E Ratio
- SY $18.08
- AVTX N/A
- Revenue Growth
- SY 3.87
- AVTX N/A
- 52 Week Low
- SY $0.66
- AVTX $4.35
- 52 Week High
- SY $1.42
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- SY 40.78
- AVTX 54.79
- Support Level
- SY $0.87
- AVTX $6.38
- Resistance Level
- SY $0.94
- AVTX $8.90
- Average True Range (ATR)
- SY 0.04
- AVTX 1.13
- MACD
- SY -0.01
- AVTX 0.08
- Stochastic Oscillator
- SY 3.56
- AVTX 33.61
About SY So-Young International Inc. American Depository Shares
So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenues from information services fees and reservation services fees from medical aesthetic service providers.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).